Speech Entrainment for Aphasia Recovery (SpARc)

June 26, 2023 updated by: Leonardo Bonilha, Medical University of South Carolina

After a stroke, many people experience a language impairment called aphasia. One of the most debilitating types of aphasia is non-fluent aphasia. Non-fluent aphasia is defined by significantly reduced speech production, with the speaker producing only a few words or even less. Speech entrainment therapy (SET) is a treatment that has been shown to increase fluency in people with non-fluent aphasia. The study looks to define the best dose of SET that leads to sustained improvements in spontaneous speech production.

Participants who are eligible will undergo baseline language testing, an MRI, and will be randomized into one of 4 treatment groups: SET for 3 weeks, SET for 4.5 weeks, SET for 6 weeks, and no treatment (control group).

Study Overview

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Stephanie Cute, CCC-SLP
  • Phone Number: (843) 792-3678
  • Email: cute@musc.edu

Study Locations

    • South Carolina
      • Charleston, South Carolina, United States, 29401
        • Recruiting
        • Medical University of South Carolina
        • Principal Investigator:
          • Janina Wilmskoetter, PhD
        • Contact:
          • Stephanie Cute, CCC-SLP
          • Phone Number: 843-792-3678
          • Email: cute@musc.edu
      • Columbia, South Carolina, United States, 29208
        • Recruiting
        • University of South Carolina
        • Contact:
        • Principal Investigator:
          • Julius Fridriksson, PhD
    • Utah
      • Salt Lake City, Utah, United States, 84112
        • Recruiting
        • University of Utah
        • Contact:
        • Principal Investigator:
          • Robert Kraemer, PhD
        • Principal Investigator:
          • Julie Wambaugh, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 81 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria

  • Aphasia as a result of a left hemisphere ischemic or hemorrhagic stroke (WAB-R Aphasia Quotient <93.8).
  • Presence of left hemisphere stroke in clinical imaging (CT/MRI) and NIHSS
  • Participants must have spoken English as their primary language.
  • 21-81 years old
  • Pre-stroke modified Rankin Scale (mRS)= 2 or less
  • Post-stroke mRS= 4 or less.
  • At least 6 months post-stroke.
  • Non-fluent aphasia (WAB-R Comprehension score >4 and WAB-R Fluency score <6).
  • Technological compatibility (to be determined by clinical judgment of SLP)

Exclusion Criteria

  • History of chronic neurological or psychiatric diseases (excluding migraines, depression, or post-stroke epilepsy). Self-reported history of learning disability.
  • Severe dysarthria (determined via SLP clinical judgment from spontaneous speech tasks on the ASRS 3.0).
  • Global aphasia.
  • History of right-hemisphere strokes or brain stem/cerebellar strokes with persistent deficits (as evidenced by MRI/CT and NIHSS).
  • Uncorrectable hearing as determined by the SLP's clinical judgment.
  • Uncorrectable vision.
  • Contraindications to MRI or inability to complete the MRI scanning session.
  • Women who are pregnant.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SET (Speech Entrainment Therapy) 3 weeks
3 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
Experimental: SET (Speech Entrainment Therapy) 4.5 weeks
4.5 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
Experimental: SET (Speech Entrainment Therapy) 6 weeks
6 weeks of SET which consists of practicing fluent speech in real time with an audio-visual computer program
Other: No Therapy 6 weeks
Participants will not be getting any SET for 6 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Verbs Per Minute (VPM) in Speech Sample
Time Frame: 3 months after treatment (or no treatment)

VPM will be assessed through procedural storytelling and narrative story telling tasks - with four items in each category. The procedural storytelling items are: 1) how to make a peanut butter and jelly sandwich, 2) how to make scrambled eggs, 3) how to brew coffee, and 4) how to wash dishes.

The narrative items will be: 1) Cinderella story, 2) Little Red Riding Hood, 3) The Three Little Pigs, and 4) Goldilocks.

3 months after treatment (or no treatment)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stroke and Aphasia Quality of Life Scale-39 (SAQOL-39)
Time Frame: 3 months after treatment (or no treatment)
We will estimate the dose of SET for individuals with non-fluent aphasia that has the highest effect size on SAQOL-39g.
3 months after treatment (or no treatment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Leonardo Bonilha, MD, PhD, Emory University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 21, 2020

Primary Completion (Estimated)

April 1, 2025

Study Completion (Estimated)

October 1, 2025

Study Registration Dates

First Submitted

April 23, 2020

First Submitted That Met QC Criteria

April 23, 2020

First Posted (Actual)

April 28, 2020

Study Record Updates

Last Update Posted (Actual)

June 27, 2023

Last Update Submitted That Met QC Criteria

June 26, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 00091924
  • U01DC017521-01A1 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on SET (Speech Entrainment Therapy) 3 weeks

3
Subscribe